このページの翻訳は実験的なもので、現在開発中です。お待ちしております
Boston Scientific バランスシートの健全性
財務の健全性 基準チェック /56
Boston Scientificの総株主資本は$20.2B 、総負債は$10.6Bで、負債比率は52.6%となります。総資産と総負債はそれぞれ$36.7Bと$16.5Bです。 Boston Scientificの EBIT は$2.5Bで、利息カバレッジ比率10.2です。現金および短期投資は$2.3Bです。
主要情報
51.3%
負債資本比率
US$10.57b
負債
| インタレスト・カバレッジ・レシオ | 10.7x |
| 現金 | US$2.91b |
| エクイティ | US$20.61b |
| 負債合計 | US$16.50b |
| 総資産 | US$37.11b |
財務の健全性に関する最新情報
Is Boston Scientific (NYSE:BSX) Using Too Much Debt?
May 10
Is Boston Scientific (NYSE:BSX) A Risky Investment?
Feb 02Does Boston Scientific (NYSE:BSX) Have A Healthy Balance Sheet?
Nov 03Boston Scientific (NYSE:BSX) Seems To Use Debt Quite Sensibly
Jul 25Here's Why Boston Scientific (NYSE:BSX) Can Manage Its Debt Responsibly
Apr 18Recent updates
Boston Scientific Corporation's (NYSE:BSX) P/E Still Appears To Be Reasonable
Sep 09A Look At The Fair Value Of Boston Scientific Corporation (NYSE:BSX)
Aug 23The Strong Earnings Posted By Boston Scientific (NYSE:BSX) Are A Good Indication Of The Strength Of The Business
Aug 08Boston Scientific Q2 Earnings Preview: Can The Rally Continue?
Jul 17Here's Why We Think Boston Scientific (NYSE:BSX) Is Well Worth Watching
Jul 05Should You Investigate Boston Scientific Corporation (NYSE:BSX) At US$77.00?
Jun 21Boston Scientific Has Become A Standout Growth Story In Med-Tech
Jun 13Why We're Not Concerned About Boston Scientific Corporation's (NYSE:BSX) Share Price
Jun 08Is Boston Scientific (NYSE:BSX) Using Too Much Debt?
May 10Boston Scientific (NYSE:BSX) Is Reinvesting At Lower Rates Of Return
Apr 22Boston Scientific: Implications Of The Axonics-Medtronic Patent Clash
Apr 05A Look At The Fair Value Of Boston Scientific Corporation (NYSE:BSX)
Mar 26We Ran A Stock Scan For Earnings Growth And Boston Scientific (NYSE:BSX) Passed With Ease
Feb 29What You Can Learn From Boston Scientific Corporation's (NYSE:BSX) P/E
Feb 15Is Boston Scientific (NYSE:BSX) A Risky Investment?
Feb 02Boston Scientific (NYSE:BSX) Could Be Struggling To Allocate Capital
Jan 19Boston Scientific: Portfolio Updates Driving Top-Line Growth
Jan 17Boston Scientific: Continued M&A Drives More Growth
Jan 10Is Boston Scientific Corporation (NYSE:BSX) Worth US$56.1 Based On Its Intrinsic Value?
Dec 04Does Boston Scientific (NYSE:BSX) Have A Healthy Balance Sheet?
Nov 03Boston Scientific: Delivering Strong Growth, But Sector Derating Is A Big Issue
Oct 30ADVENT Offers Up An Early Present For Boston Scientific Investors
Aug 28Estimating The Fair Value Of Boston Scientific Corporation (NYSE:BSX)
Aug 24Boston Scientific (NYSE:BSX) Seems To Use Debt Quite Sensibly
Jul 25Boston Scientific Remains Operationally Sound But May Have Limited Upside
Jul 14Investors Could Be Concerned With Boston Scientific's (NYSE:BSX) Returns On Capital
Jul 10Boston Scientific Corporation (NYSE:BSX) Shares Could Be 29% Above Their Intrinsic Value Estimate
May 21Here's Why Boston Scientific (NYSE:BSX) Can Manage Its Debt Responsibly
Apr 18Returns On Capital At Boston Scientific (NYSE:BSX) Paint A Concerning Picture
Apr 03Boston Scientific Stands Out With Strong, Diversified Growth Profile
Feb 15財務状況分析
短期負債: BSXの 短期資産 ( $8.2B ) が 短期負債 ( $4.9B ) を超えています。
長期負債: BSXの短期資産 ( $8.2B ) は 長期負債 ( $11.6B ) をカバーしていません。
デット・ツー・エクイティの歴史と分析
負債レベル: BSXの 純負債対資本比率 ( 37.1% ) は 満足できる 水準であると考えられます。
負債の削減: BSXの負債対資本比率は、過去 5 年間で99.9%から52.6%に減少しました。
債務返済能力: BSXの負債は 営業キャッシュフロー によって 十分にカバー されています ( 23.3% )。
インタレストカバレッジ: BSXの負債に対する 利息支払い は EBIT ( 10.2 x coverage) によって 十分にカバーされています。